These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29772837)

  • 1. Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.
    van Steenhoven JEC; Kuijer A; van Diest PJ; van Gorp JM; Straver M; Elias SG; Wesseling J; Rutgers E; Timmer-Bonte JNH; Nieboer P; Smilde TJ; Imholz A; Blanken CFJM; Siesling S; van Dalen T
    Genes (Basel); 2018 May; 9(5):. PubMed ID: 29772837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
    Viale G; de Snoo FA; Slaets L; Bogaerts J; van 't Veer L; Rutgers EJ; Piccart-Gebhart MJ; Stork-Sloots L; Glas A; Russo L; Dell'Orto P; Tryfonidis K; Litière S; Cardoso F;
    Breast Cancer Res Treat; 2018 Jan; 167(1):123-131. PubMed ID: 28929359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
    Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
    Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
    Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
    Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
    Lundgren C; Bendahl PO; Borg Å; Ehinger A; Hegardt C; Larsson C; Loman N; Malmberg M; Olofsson H; Saal LH; Sjöblom T; Lindman H; Klintman M; Häkkinen J; Vallon-Christersson J; Fernö M; Rydén L; Ekholm M
    Breast Cancer Res Treat; 2019 Nov; 178(2):459-467. PubMed ID: 31432367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.
    Groenendijk FH; Treece T; Yoder E; Baron P; Beitsch P; Audeh W; Dinjens WNM; Bernards R; Whitworth P
    NPJ Breast Cancer; 2019; 5():15. PubMed ID: 31016233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical impacts of molecular subtyping by multigene assay on hormone receptor-positive breast cancers.
    Liu YL; Hsu CY; Feng CJ; Lien PJ; Huang CC; Lin YS; Wang YL; Chao TC; Liu CY; Chiu JH; Tsai YF; Tseng LM
    J Chin Med Assoc; 2022 Mar; 85(3):324-330. PubMed ID: 34907993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods.
    Focke CM; van Diest PJ; Decker T
    Breast Cancer Res Treat; 2016 Sep; 159(2):257-63. PubMed ID: 27558625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
    Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
    Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.
    Myburgh EJ; Langenhoven L; Grant KA; van der Merwe L; Kotze MJ
    J Glob Oncol; 2017 Aug; 3(4):314-322. PubMed ID: 28831439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
    Murase K; Yanai A; Saito M; Imamura M; Miyagawa Y; Takatsuka Y; Inoue N; Ito T; Hirota S; Sasa M; Katagiri T; Fujimoto Y; Hatada T; Ichii S; Nishizaki T; Tomita N; Miyoshi Y
    Breast Cancer; 2014 Jan; 21(1):52-7. PubMed ID: 22359195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
    Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
    Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
    Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
    J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.
    Kuijer A; Straver M; den Dekker B; van Bommel ACM; Elias SG; Smorenburg CH; Wesseling J; Linn SC; Rutgers EJT; Siesling S; van Dalen T
    J Clin Oncol; 2017 Aug; 35(24):2814-2819. PubMed ID: 28813638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.